"Dr. Philip Bergman, a Director at VCA, one of our potential private clinic consortium partners, emphasized the importance of publishing in the VCS proceedings.
Mike Korenko, Vivos CEO, said, “Our intent is to use the VCS conference to identify a list of initial users of IsoPet®. We plan to select the optimum candidates in each of our targeted regions across the United States. We will offer to provide certification training and assist them in obtaining their radioactive material handling licenses. I am excited to be taking this important step. The animal testing has a dual purpose. It is also a key pre-clinical test to support human skin cancer therapy.” https://globenewswire.com/news-release/2018/08/02/1546056/0/en/Vivos-Inc-Sets-the-Stage-for-the-Introduction-of-IsoPet-RadioGel-to-the-Veterinarian-Community.html
Market Data 
Markets 
